Roivant Sciences (ROIV) Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Roivant's Anti-Inflammatory Drug Succeeds in Mid-Stage Study usnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usnews.com Daily Mail and Mail on Sunday newspapers.
Roivant Sciences said on
Tuesday its experimental drug to treat non-infectious uveitis
helped reduce symptoms of the inflammatory eye disease in a
mid-stage study. In the study testing.
Roivant (ROIV) and Priovant Therapeutics reported positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, showing the strongest efficacy data in NIU observed to date.
Roivant Sciences' experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's.